https://ajhponline.com/index.php/journal <p><strong>Asian Journal of Hospital Pharmacy (<em>Asian Jour Hosp Phar</em>)</strong>&nbsp; &nbsp;is a double-blind Peer-Reviewed Quarterly open access international journal dedicated to the promotion of research Pharmaceutical sciences. We define Open Access journals as journals that use a funding model that does not charge readers or their institutions for access. The journal publishes Research articles, Review article, Case Reports, and Short communication from broad areas like Pharmacy practice,&nbsp; Clinical Pharmacy, Hospital Pharmacy, Pharmacotherapeutics Pharmacoepidemiology and Economics, Clinical Research, Pharmaceutics, Pharmacology, Pharmacognosy &amp; Phytochemistry, Pharmaceutical Chemistry, Pharmaceutical Biotechnology, Pharmaceutical Analysis,&nbsp; Pharmacogenomics, Medicinal Chemistry, Molecular Pharmacology, Novel drug delivery system, Nanotechnology, Analytical Chemistry, Organic Chemistry, Natural Chemistry, Polymer Sciences, and Biotechnology, etc.</p> <p><strong>Road Indexing:</strong> https://portal.issn.org/resource/ISSN/2583-0724</p> <p><strong>Open Access Policy</strong></p> <p>All the Published articles By the Asian Journal of Hospital Pharmacy (AJHP) are available Worldwide Under the Open Access Policy. As per the Budapest Open Access Initiative, Readers can Directly Access Published articles without paying any subscription or access fees. Readers are allowed to read, download, copy and distribute the full text of all published articles, and readers can Utilize the published article for Non-Commercial Purpose.</p> <p><strong>Data Preservation</strong></p> <p><strong>Asian Journal of Hospital Pharmacy (AJHP)</strong>Preserved all published data content in&nbsp;PORTICO</p> AJHP Publisher en-US Asian Journal of Hospital Pharmacy 2583-0724 <p>Copyright © Author(s) retain the copyright of this article.</p> https://ajhponline.com/index.php/journal/article/view/92 <p>Single-use technologies (SUT) have revolutionized the bio manufacturing industry by offering flexibility, cost efficiency, and improved contamination control. Initially adopted for simpler processes, SUT has expanded to complex bioprocessing operations, driven by the growing demand for biologics, vaccines, and personalized medicines. This review explores the benefits of SUT, including reduced capital and operational expenditures, faster setup and turnaround times, and enhanced product safety. The scalability of SUT allows for rapid adaptation to market demands, significantly accelerating the time-to-market for critical therapies. However, the implementation of SUT is not without challenges. Material compatibility, leachables, waste management, and supply chain reliability pose significant hurdles. Moreover, regulatory and validation challenges complicate the adoption of these technologies in large-scale production. Case studies, including the rapid deployment of COVID-19 vaccines and the production of monoclonal antibodies, illustrate SUT's practical applications and benefits. The review also examines future trends, highlighting advances in materials, automation, and digital integration, as well as the expanding applications of SUT in cell and gene therapy manufacturing. As the bio manufacturing landscape continues to evolve, SUT will play a crucial role in meeting the industry's growing needs, provided the challenges associated with its implementation are effectively managed.</p> Sanket J Soni Ankitkumar N Patel Copyright (c) 2024 https://creativecommons.org/licenses/by-nc/4.0 2024-10-21 2024-10-21 1 7 10.38022/ajhp.v4i4.92 https://ajhponline.com/index.php/journal/article/view/93 <p>Upper respiratory tract infection (URI) is a general term for a heterogeneous group of illnesses caused by numerous etiologic agents that affect the mucosal lining of the upper respiratory tract, including the middle-ear cavity and par nasal sinuses. URIs are primarily caused by viruses, rhinoviruses being the most common etiological agents. Respiratory viruses transmit easily via direct contact or aerosols. The incidence of URI is highest in children who suffer 6–8 infections per year. The main symptoms of URI are nasal blockage and discharge, sneezing, sore throat, and cough. Fever occurs variably, most commonly in children. Viral URIs often predispose to bacterial complications. Acute otitis media is the most common complication in children, whereas sinusitis and pneumonia are more frequent in adults and the elderly. The treatment of URI is mainly symptomatic because specific antiviral are available only for influenza viruses. Antibiotics have no efficacy for viral URI but are commonly used for treating acute otitis media and sinusitis. Most URIs are self-limited illnesses with an average duration of 7–10 days and an excellent prognosis.</p> Vijaya Sree K Saranya K Vandana singh JK Narayana Swamy P Ramesh Y Prapurna Chandra Y Copyright (c) 2024 https://creativecommons.org/licenses/by-nc/4.0 2024-12-26 2024-12-26 8 12 10.38022/ajhp.v4i4.93